Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Conditions

• PDAC
• PDAC - Pancreatic Ductal Adenocarcinoma
• Pancreatic Cancer
• Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
• Resected Pancreatic Adenocarcinoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• daraxonrasib — DRUG
  oral tablets

Study Details

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

Key Dates

First listed

Nov 26, 2025

Start date

Dec 15, 2025

Status verified

Aug 2026

Primary completion

May 10, 2029

Completion

Jul 10, 2030

Study Design

Enrollment

500 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: daraxonrasib
  study drug
• No Intervention: SOC Observation
  Patients randomized to the comparator control arm will receive SOC observation.

Primary Outcome Measure

Disease-Free Survival (DFS) per Investigator [ Time Frame: Up to approximately 5 years ]

Central Contacts

• Revolution Medicines Study Director
  1-844-2-REVMED
  [email protected]

Locations (35)

Find similar trials in Phoenix, AZ

Related Studies

• Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
  Recruiting · Mayo Clinic · Phoenix, Arizona
• Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
  Recruiting · Vanderbilt University Medical Center · Nashville, Tennessee
• PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic Disease
  Recruiting · Columbia University · New York, New York
• Pancreatic Cancer Genetics
  Recruiting · Columbia University · New York, New York